## CLAIMS

## What is claimed is:

- 1. A method for directly identifying a candidate compound as a compound selected from the group consisting of an inverse agonist, a partial agonist and an agonist, to an endogenous, constitutively active G protein coupled orphan receptor, comprising the steps of:
  - (a) contacting a candidate compound with GPCR Fusion Protein, said GPCR Fusion

    Protein comprising an endogenous, constitutively active G protein coupled orphan
    receptor and a G protein; and
  - (b) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound is an inverse agonist, a partial agonist or an agonist of said receptor.
- The method of claim 1 wherein the compound is directly identified as an inverse agonist to said orphan receptor.
- 3. The method of claim 1 wherein the compound is directly identified as an agonist to said orphan receptor.
- 4. The method of claim 1 wherein the compound is directly identified as partial agonist to said orphan receptor.
  - 5. A composition comprising a compound identified by the method of claim 2.
  - 6. A composition comprising a compound identified by the method of claim 3.
  - 7. A composition comprising a compound identified by the method of claim 4.
  - 8. The method of claim 1 wherein said orphan receptor is selected from the group consisting of: GPR3, GPR4, GPR6, GPR12, GPR21, OGR1, GHSR, RE2 and ALO22171.

- 9. The method of claim 1 wherein said orphan receptor is GPR6.
- 10. The method of claim 1 wherein said G protein is selected from the group consisting of: Gs, Gi, Gq and Go.
- 11. The method of claim 1 wherein said G protein is Gsa.

ŵ

- 12. A method for directly identifying a candidate compound as a compound selected from the group consisting of an inverse agonist, a partial agonist and an agonist, to an endogenous, constitutively active G protein coupled orphan receptor, comprising the steps of:
  - (a) contacting a candidate compound with GPCR Fusion Protein, said GPCR Fusion

    Protein comprising an endogenous, constitutively active G protein coupled orphan
    receptor and a Gsα protein; and
  - (b) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound is an inverse agonist, a partial agonist or an agonist of said receptor.
  - 13. The method of claim 12 wherein said orphan receptor is selected from the group consisting of: GPR3, GPR4, GPR6, GPR12, GPR21, OGR1, GHSR, RE2 and ALO22171.
  - 14. The method of claim 12 wherein said orphan receptor is GPR6.
  - 15. The method of claim 14 wherein said compound is directly identified as a compound selected from the group consisting of an inverse agonist and an agonist.
  - 16. The method of claim 15 wherein said compound is an inverse agonist.
  - 17. A composition comprising the compound of claim 16.
  - 18. A method for modulating a G protein coupled oprhan receptor comprising the step of contacting said receptor with a compound identified by the method of claim 1.

19. A method for modulating a G protein coupled oprhan receptor comprising contacting said receptor with a compound identified by the method of claim 12.